Histavert 16 Tablet contains Betahistine 16 mg, a histamine analog used primarily in the management of Ménière’s disease and other vestibular disorders. Betahistine acts by improving microcirculation in the inner ear, thereby reducing the pressure caused by excessive endolymphatic fluid. This pharmacological effect helps alleviate symptoms such as vertigo, tinnitus, hearing loss, and dizziness associated with vestibular dysfunction. Histavert 16 is indicated for patients experiencing recurrent episodes of vertigo and balance disturbances linked to inner ear pathology. The tablet is administered orally, with dosing tailored according to clinical response and patient tolerance. Betahistine exhibits a favorable safety profile, with adverse effects generally mild and infrequent, including gastrointestinal discomfort and headache. It is contraindicated in patients with pheochromocytoma due to its potential to provoke hypertensive crises. Caution is advised in individuals with a history of peptic ulcers or asthma. Histavert 16 should be used under medical supervision, ensuring proper diagnosis and monitoring of therapeutic outcomes. By enhancing vestibular compensation and reducing endolymphatic pressure, Histavert 16 offers symptomatic relief and improved quality of life for patients suffering from vestibular disorders.